NCT05802056 - Aldesleukin with Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer with Peritoneal Metastasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Clinical Stage IV Gastric Cancer AJCC V8Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaMetastatic Gastric CarcinomaMetastatic Malignant Neoplasm in the Peritoneum

Interventions

BIOLOGICAL

Aldesleukin

Given IP

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood and tissue samples

PROCEDURE

Computed Tomography

Undergo PET/CT

PROCEDURE

Diagnostic Laparoscopy

Undergo diagnostic laparoscopy

DRUG

Fluorouracil

Given IV

DRUG

Leucovorin Calcium

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo PET/MRI

BIOLOGICAL

Nivolumab

Given IV

DRUG

Oxaliplatin

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT or PET/MRI

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester